England’s National Health Service will make ruxolitinib cream available for vitiligo patients aged 12 and older, marking the first time a drug targeting the condition’s direct biological cause has been approved for NHS use.
Sold under the brand name Opzelura, the cream works by inhibiting two enzymes that prompt immune cells to attack melanocytes — the cells responsible for producing the pigment melanin. Existing options, such as steroid creams, suppress immune function broadly rather than acting on the specific pathway that drives the condition.
David Rosmarin at Indiana University, who led two trials of the treatment, notes that vitiligo patients are typically “asymptomatic in terms of physical symptoms, but it can cause a lot of emotional hardship.” The condition affects roughly 1 percent of the global population and produces pale, depigmented skin patches. Non-segmental vitiligo — the form the cream treats — appears symmetrically on both sides of the body.
Trial Results and NHS Access
Two trials published in 2022 found that the cream increased pigmentation and reduced the visibility of vitiligo patches compared with a placebo, across all skin tones. In more than a third of participants who stopped using the drug after the trial, results held for at least a year.
The National Institute for Health and Care Excellence (NICE) previously reviewed ruxolitinib and rejected it on cost-effectiveness grounds. The agency has since reversed course, now recommending it for patients where other topical treatments have failed or are unsuitable.
Emma Rush at Vitiligo Support UK called the decision significant: “That’s why this is such a landmark.” The cream is already available in the United States.
Safety Profile and Wider Context
An oral form of ruxolitinib, used to treat certain cancers and rheumatoid arthritis, carries serious risk — including lymphoma, heart complications, and severe infections. None of those effects have appeared with the topical version. In the vitiligo trials, side effects were limited to mild acne and itchiness.
Viktoria Eleftheriadou at the British Association of Dermatologists noted “super minimal systemic absorption” with the cream. The drug is also considered safer than steroid creams, which can thin the skin with prolonged use.
Despite the approval, attitudes among patients differ. Natalie Ambersley, a vitiligo ambassador for the charity Changing Faces, said she won’t pursue the treatment after years on existing options. “I’ve learned to accept my skin,” she said. Rush offered a counterpoint: “It’s great that there are people who love the skin they’re in, but that’s not for everyone.”
Eleftheriadou acknowledged that both patients and clinicians sometimes dismiss vitiligo as trivial — “it doesn’t kill you, it’s not painful” — but the condition carries documented risk of depression and anxiety, and in some cases produces large, inflamed or discoloured patches.
Photo by cottonbro studio on Pexels
This article is a curated summary based on third-party sources. Source: Read the original article
